Batroxobin also attenuates the scar formation (48), display a direct neuroprotective effect on anoxic neuron (49) and delay the onset and the course of demyelinating disease; (50, 51) possible mechanisms include relieving inflammation (48, 51), decreasing the deposition of fibrin, down-regulating the expression of phospho-Akt (p-Akt), and up-regulating the expression of myelin basic protein (MBP) (51). The gene discussed is AKT1; the disease is demyelinating disease.